Absci (ABSI) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Absci (NASDAQ: ABSI):

• 7/2/2026 – Absci had its price target raised by Truist Financial Corporation from $11.00 to $17.00. They now have a “buy” rating on the stock.
• 6/27/2026 – Absci was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/25/2026 – Absci had its “positive” rating reaffirmed by Morgan Stanley. They now have a $10.00 price target on the stock.
• 6/25/2026 – Absci had its price target raised by HC Wainwright from $8.00 to $16.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Absci had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock, up from $7.00.
• 6/24/2026 – Absci had its price target raised by BTIG Research from $9.00 to $13.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Absci had its price target raised by Guggenheim from $10.00 to $15.00. They now have a “buy” rating on the stock.
• 6/4/2026 – Absci is now covered by Leerink Partners. They set an “outperform” rating and a $12.00 price target on the stock.
• 5/28/2026 – Absci is now covered by BTIG Research. They set a “buy” rating and a $9.00 price target on the stock.
• 5/28/2026 – Absci is now covered by BTIG Research. They set a “buy” rating and a $9.00 price target on the stock.
• 5/14/2026 – Absci was given a new $4.10 price target by Morgan Stanley.
• 5/8/2026 – Absci had its price target raised by Truist Financial Corporation from $9.00 to $11.00. They now have a “buy” rating on the stock.

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.